Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA0.41%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

Recommended Videos To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in Europe containing glatiramer acetate, the commission ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone. The ...

Teva says it plans to file the drug with the FDA later this year in both episodic and chronic migraine, anticipating approval and launch in the second half next year. Patients in the episodic ...

Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those ...

Teva recorded double-digit sales growth in generic drugs as well as in sales of its trio of key branded medicines. "2025 will be a bit of more of the same - more innovative growth, the ability to ...

TEVA) EUR 462.6M, or around $500M, for trying to ward off competition for its blockbuster multiple sclerosis drug Copaxone in Europe by disparaging a rival product. The commission found that Teva ...

To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in Europe containing glatiramer acetate, the commission said in a statement.

Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact ...